GPR171: A GPCR Targeted for Therapeutic Development (G29909)
GPR171: A GPCR Targeted for Therapeutic Development
GPR171 (H963) is a G protein-coupled receptor (GPCR) that is expressed in various tissues and cells in the body. It is a key regulator of cellular processes such as sensory perception, neurotransmitter signaling, and stem cell proliferation. GPR171 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. As a result, GPR171 has become a focus of interest in drug development, as potential therapeutic targets or biomarkers.
The GPCR family of proteins consists of over 700 members, and GPR171 is one of the most well-studied members. GPR171 is a small GPCR that is expressed in the brain, heart, liver, and kidneys. It is a single transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain of GPR171 contains a N-terminal region that is involved in protein-protein interactions and is known as the N-terminus. The transmembrane domain of GPR171 is responsible for the stability and localization of the receptor in the cell membrane, and the intracellular domain is involved in the regulation of gene expression.
GPR171 has been shown to play a role in a variety of physiological processes. For example, GPR171 is involved in the regulation of neurotransmitter signaling, which is critical for brain function. Studies have shown that GPR171 is involved in the regulation of dopamine (D2) receptor function, which is involved in motor control, mood regulation, and other physiological processes. In addition, GPR171 has been shown to be involved in the regulation of pain perception, which is a critical aspect of neuropathic pain.
GPR171 has also been shown to be involved in the regulation of stem cell proliferation. Stem cells are a critical cell type that have the ability to give rise to many different cell types in the body. GPR171 has been shown to play a role in the regulation of stem cell proliferation by promoting the growth and survival of stem cells. This is important for the development of new treatments for diseases such as cancer, as stem cells have the potential to be used to generate healthy cells to replace those that are damaged or destroyed by disease.
In addition to its role in stem cell biology, GPR171 has also been shown to be involved in the regulation of other cellular processes. For example, GPR171 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues. GPR171 has also been shown to be involved in the regulation of inflammation, which is a critical aspect of immune response.
GPR171 has also been implicated in a variety of diseases. For example, GPR171 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, GPR171 has also been shown to be involved in the regulation of cancer cell growth and metastasis. This is important for the development of new treatments for cancer, as cancer cells are a major challenge for cancer therapists.
GPR171 has also been shown to be involved in the regulation of cardiovascular disease. Studies have shown that GPR171 is involved in the regulation of angiotensin II signaling, which is a critical aspect of cardiovascular disease. Angiotensin II is a hormone that is involved in the regulation of blood pressure and blood vessel diameter. In addition, GPR171 has also been shown to be involved in the regulation of nitric oxide (NO) signaling, which is important for cardiovascular
Protein Name: G Protein-coupled Receptor 171
Functions: G-protein coupled receptor for Big LEN, a 16-amino acid neuropeptide produced from the precursor protein, proSAAS (encoded by PCSK1N). Acts through a G(i)-alpha-mediated pathway in response to Big LEN. Big LEN-GPR171 system plays an important role in regulating feeding and metabolism. Also plays a role in modulating fear and anxiety-like behaviors in the basolateral amygdala. Big LEN-GPR171 modulates the mu-type opioid receptor signaling and antinociception (By similarity). Acts as a negative regulator T cell function (PubMed:34615877)
The "GPR171 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR171 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2 | GRB7
